Cargando…

Organoid technology in disease modelling, drug development, personalized treatment and regeneration medicine

Organoid technology bridges the gap between conventional two-dimensional cell line culture and in vivo models. The near-physiological technology can virtually recapitulates organ development and human diseases, such as infectious diseases, genetic abnormality and even cancers. In addition, organoids...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Hanxiao, Jiao, Ying, Qin, Shuang, Zhao, Weiheng, Chu, Qian, Wu, Kongming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282260/
https://www.ncbi.nlm.nih.gov/pubmed/30534474
http://dx.doi.org/10.1186/s40164-018-0122-9
_version_ 1783378952689025024
author Xu, Hanxiao
Jiao, Ying
Qin, Shuang
Zhao, Weiheng
Chu, Qian
Wu, Kongming
author_facet Xu, Hanxiao
Jiao, Ying
Qin, Shuang
Zhao, Weiheng
Chu, Qian
Wu, Kongming
author_sort Xu, Hanxiao
collection PubMed
description Organoid technology bridges the gap between conventional two-dimensional cell line culture and in vivo models. The near-physiological technology can virtually recapitulates organ development and human diseases, such as infectious diseases, genetic abnormality and even cancers. In addition, organoids can more accurately predict drug responses, and serve as an excellent platform for drug development, including efficacy evaluation, toxicity testing and pharmacokinetics analysis. Furthermore, organoids can also be exploited to explore the possible optimized treatment strategies for each individual patient. Besides, organoid technology is a promising strategy for regeneration medicine and transplantation use, which can overcome the deficiency in the supply of healthy donor tissues and inherent immunological rejection through establishing isogenic organoids from minuscule amounts of patient biopsies. Collectively, organoids hold enormous potential for clinical applications and bring basic research closer to clinical practice. In this review, we described common organoid lines, summarized the potential clinical applications, and outlined the current limitations.
format Online
Article
Text
id pubmed-6282260
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-62822602018-12-10 Organoid technology in disease modelling, drug development, personalized treatment and regeneration medicine Xu, Hanxiao Jiao, Ying Qin, Shuang Zhao, Weiheng Chu, Qian Wu, Kongming Exp Hematol Oncol Review Organoid technology bridges the gap between conventional two-dimensional cell line culture and in vivo models. The near-physiological technology can virtually recapitulates organ development and human diseases, such as infectious diseases, genetic abnormality and even cancers. In addition, organoids can more accurately predict drug responses, and serve as an excellent platform for drug development, including efficacy evaluation, toxicity testing and pharmacokinetics analysis. Furthermore, organoids can also be exploited to explore the possible optimized treatment strategies for each individual patient. Besides, organoid technology is a promising strategy for regeneration medicine and transplantation use, which can overcome the deficiency in the supply of healthy donor tissues and inherent immunological rejection through establishing isogenic organoids from minuscule amounts of patient biopsies. Collectively, organoids hold enormous potential for clinical applications and bring basic research closer to clinical practice. In this review, we described common organoid lines, summarized the potential clinical applications, and outlined the current limitations. BioMed Central 2018-12-05 /pmc/articles/PMC6282260/ /pubmed/30534474 http://dx.doi.org/10.1186/s40164-018-0122-9 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Xu, Hanxiao
Jiao, Ying
Qin, Shuang
Zhao, Weiheng
Chu, Qian
Wu, Kongming
Organoid technology in disease modelling, drug development, personalized treatment and regeneration medicine
title Organoid technology in disease modelling, drug development, personalized treatment and regeneration medicine
title_full Organoid technology in disease modelling, drug development, personalized treatment and regeneration medicine
title_fullStr Organoid technology in disease modelling, drug development, personalized treatment and regeneration medicine
title_full_unstemmed Organoid technology in disease modelling, drug development, personalized treatment and regeneration medicine
title_short Organoid technology in disease modelling, drug development, personalized treatment and regeneration medicine
title_sort organoid technology in disease modelling, drug development, personalized treatment and regeneration medicine
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282260/
https://www.ncbi.nlm.nih.gov/pubmed/30534474
http://dx.doi.org/10.1186/s40164-018-0122-9
work_keys_str_mv AT xuhanxiao organoidtechnologyindiseasemodellingdrugdevelopmentpersonalizedtreatmentandregenerationmedicine
AT jiaoying organoidtechnologyindiseasemodellingdrugdevelopmentpersonalizedtreatmentandregenerationmedicine
AT qinshuang organoidtechnologyindiseasemodellingdrugdevelopmentpersonalizedtreatmentandregenerationmedicine
AT zhaoweiheng organoidtechnologyindiseasemodellingdrugdevelopmentpersonalizedtreatmentandregenerationmedicine
AT chuqian organoidtechnologyindiseasemodellingdrugdevelopmentpersonalizedtreatmentandregenerationmedicine
AT wukongming organoidtechnologyindiseasemodellingdrugdevelopmentpersonalizedtreatmentandregenerationmedicine